Abstract
Circulating tumour DNA (ctDNA) shows promise as a minimally invasive
biomarker with a myriad of emerging applications including early detection
and diagnosis, monitoring of disease and treatment efficacy, and identification
of actionable alterations to guide treatment. The potential utility of ctDNA in
colorectal carcinoma (CRC) is of particular interest given the limitations of current radiographic imaging and blood-based tumour markers in detecting disease and evaluating therapeutic benefit. While ctDNA has yet to demonstrate clinical utility in CRC, a growing body of research highlights the potential of these novel biomarkers. This chapter provides an overview of the current evidence for employing ctDNA in CRC as well as previewing the future directions that these exciting technologies may take.
biomarker with a myriad of emerging applications including early detection
and diagnosis, monitoring of disease and treatment efficacy, and identification
of actionable alterations to guide treatment. The potential utility of ctDNA in
colorectal carcinoma (CRC) is of particular interest given the limitations of current radiographic imaging and blood-based tumour markers in detecting disease and evaluating therapeutic benefit. While ctDNA has yet to demonstrate clinical utility in CRC, a growing body of research highlights the potential of these novel biomarkers. This chapter provides an overview of the current evidence for employing ctDNA in CRC as well as previewing the future directions that these exciting technologies may take.
| Original language | English |
|---|---|
| Title of host publication | Advances in the Molecular Understanding of Colorectal Cancer |
| Editors | Eva Segelov |
| Publisher | In-Tech |
| Chapter | 4 |
| Number of pages | 24 |
| ISBN (Electronic) | 9781789850604 |
| ISBN (Print) | 9781789850598 |
| DOIs | |
| Publication status | Published - 6 Feb 2019 |
